Variety of qualified sufferers: CDEC talked over the uncertainty in the volume of patients with reasonably intense to severe hemophilia B in Canada suitable for etranacogene dezaparvovec. Medical experts consulted by CADTH indicated that some patients who will be labeled as acquiring delicate or moderate disease may have a intense bleeding phenotyp